Clinical trials: Pandemic Influenza Prevention
Pandemic Influenza Prevention
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
- Trial name
- NCT03370289
- Testing
- BLB-750 Vaccine (Qinghai RG strain)
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Phase II Study of Pandemic Influenza Vaccine
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next influenza pandemic.
- Trial name
- NCT00320346
- Testing
- Pandemic Influenza Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of a Pandemic Influenza Vaccine
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic.
- Trial name
- NCT00136331
- Testing
- Pandemic influenza vaccine
- Where
- 2 sites in Australia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Avian
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults
This study evaluates safety, tolerability and immunogenicity of two doses of GHB04L1, a liquid formulation of the replication- deficient influenza A/Vietnam/1203/04(H5N1)-like ∆NS1 virus in healthy adults.
- Trial name
- NCT03745274
- Testing
- GHB04L1
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza
Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
To determine the tolerability and immunogenicity of FLUVAL P monovalent influenza vaccine in adults and elderly people, with the objective to verify efficacy and tolerability of the study drug.
- Trial name
- NCT01010893
- Testing
- Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pandemic Influenza, Prevention
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
A single center, randomized and double-blind phase II clinical trial is to be conducted in adults to evaluate the safety and immunogenicity of an inactivated pandemic influenza vaccine (whole-virion, aluminium-adjuvanted).
- Trial name
- NCT00535665
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Study of a Pandemic Influenza Vaccine in Children
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza strain H5N1 is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00370864
- Testing
- H5N1 pandemic influenza vaccine
- Where
- 2 sites in Australia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
To determine the tolerability and safety of FLUVAL P monovalent influenza vaccine in children.
- Trial name
- NCT01100294
- Testing
- Vaccination with FLUVAL P
- Where
- Hungary
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H5N1 Influenza
H5N1 Vaccine Study in Japanese Adults
The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.
- Trial name
- NCT01382329
- Testing
- H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
- Where
- 3 sites in Japan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309647
- Testing
- Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine, Influenza Monovalent Whole virus (H5N1)
- Where
- 9 sites in Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline